|1.||Cianciotto, Nicholas P: 2 articles (12/2014 - 05/2005)|
|2.||Johnson, Glen O: 2 articles (06/2012 - 02/2007)|
|3.||Housh, Terry J: 2 articles (06/2012 - 02/2007)|
|4.||Montaner, Joan: 2 articles (02/2012 - 09/2011)|
|5.||Penalba, Anna: 2 articles (02/2012 - 09/2011)|
|6.||Chacón, Pilar: 2 articles (02/2012 - 09/2011)|
|7.||Delgado, Pilar: 2 articles (02/2012 - 09/2011)|
|8.||Ribó, Marc: 2 articles (02/2012 - 09/2011)|
|9.||Steiner, Adrian: 2 articles (03/2010 - 07/2003)|
|10.||Meylan, Mireille: 2 articles (03/2010 - 07/2003)|
|1.||Hematologic Neoplasms (Hematological Malignancy)
02/01/1983 - "Twenty-one patients with hematopoietic malignancies including 6 previously untreated, 9 pretreated, and in relapse, 5 in complete remission and one in partial remission all were treated with PL-AC. "
01/01/1989 - "This study showed low but persistent levels of PLAC in plasma and tissues, with a continuous release of small amounts of ara-C, which demonstrated antitumor activity in patients with hematologic malignancies."
02/20/1984 - "Phase I and early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies."
02/01/1983 - "[Early phase II study of PL-AC [N4-palmitoyl-(1-beta-D-arabinofuranosyl) cytosine] on hematopoietic malignancies]."
01/01/1989 - "The pharmacokinetics of oral N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC), a lipophilic and deaminase-resistant derivative of 1-beta-D-arabinofuranosylcytosine (ara-C), were determined in patients with hematologic malignancies. "
06/01/1977 - "Single doses of PalmO-ara-C were effective against L1210 leukemic mice when administered 5 to 7 days before tumor inoculation. "
01/01/1991 - "Single-agent palmO-ara-C given at its MTD produced a similar reduction in tumor burden and increase in life span compared to the highest palmO-ara-C dose that could be given in combination with either modulator."
01/01/1991 - "The addition of DAUrd produced a modest (but statistically significant) prolongation of life span and a further 2-log10 reduction in tumor burden compared to the same dose of palmO-ara-C alone, and resulted in long-term survivors in five of 30 treated animals. "
02/25/1999 - "PLAC should be considered in the differential diagnosis of head and neck masses, where the cytology suggests one of these tumors, even when the clinical context (involvement of a major salivary gland, lymph node metastasis) is not typical of PLAC."
02/25/1999 - "Polymorphous low grade adenocarcinoma of the salivary glands (PLAC) is a low grade neoplasm that predominantly occurs in the minor salivary glands. "
08/01/1987 - "In spite of the disadvantages of the oral form of the drug, such as unpredictable absorption, PL-AC may be useful in the treatment of acute leukemia, especially that of the aged, a condition for which intensive chemotherapy is not always indicated, and MDS, which do not necessarily require admission to a hospital."
08/01/1987 - "[A phase II study of N4-palmitoyl-1-beta-D-arabinofuranosylcytosine (PL-AC) in patients with acute leukemia and myelodysplastic syndromes. "
01/01/1986 - "N4-Palmitoyl-1-beta-D-arabinofuranosylcytosine (PLAC) was administered PO to 76 patients with acute leukemia, myelodysplastic syndromes (MDSs), and myeloproliferative disorders (MPDs). "
01/01/2012 - "For the leukemia/lymphoma models, thiarabine was more efficacious than ara-C/palmO-ara-C (four models), clofarabine (three models), fludarabine monophosphate (five models), cladribine (four models), and gemcitabine (six models). "
|4.||Lymphedema (Milroy Disease)
01/01/1997 - "In the 24 patients with a more severe lymphedema, the lymphoscintigraphic parameters (m +/- sd) were as follows: lymphatic migration speed was significantly improved by Dios in comparison with Plac (delta Speed cm/minute: 0.84 +/- 0.6 vs 0.14 +/- 0.26, P = 0.005). "
01/01/1997 - "One hundred and four women with lymphedema were included; 94 completed the study (46 Dios, 48 Plac). "
01/01/1997 - "A subset of 24 patients with more severe lymphedema (10 Dios, 14 Plac) was subjected to a separate analysis. "
01/01/1997 - "To assess the activity of a purified, micronized, flavonoidic fraction (Dios; Daflon 500 mg*) on upper limb lymphedema occurring after breast cancer therapy, a monocenter, randomized, double-blind, parallel group vs placebo (Plac) trial was carried out. "
08/01/1995 - "There was no statistical evidence of efficacy of CAPS cream over PLAC for any of the pain indices. "
09/01/1997 - "The total scale of the Hamburg Pain Adjective List (HPAL) was significantly reduced in ALA 1,200 and ALA 600 compared with PLAC after 19 days (both P < 0.05). "
12/01/1995 - "The total scale of the Pain Adjective List was significantly reduced in ALA 1200 and ALA 600 as compared with PLAC after 19 days (both p < 0.01). "
01/01/2014 - "Combined with PTA drainage and IV antibiotics, 10 mg IV DEX resulted in less pain at 24 hours when compared to PLAC, without any serious side effects. "
09/01/1997 - "The total symptom score (TSS) (pain, burning, paresthesia, and numbness) in the feet decreased significantly from baseline to day 19 in ALA 1,200 and ALA 600 vs. PLAC. "
|5.||Thioctic Acid (Lipoic Acid)
|6.||Messenger RNA (mRNA)
|9.||Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
|1.||Drug Therapy (Chemotherapy)